SARS-CoV-2 neutralising antibody profiles reveal variant specific antibody dynamics and regional differences in infection histories in Malawi
8 affiliations
- 1MRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom of Great Britain and Northern Ireland
- 2Malawi Epidemiology and Intervention Research Unit (MEIRU), Karonga, Malawi
- 3The Roslin Institute and R(D)SVS, University of Edinburgh, Edinburgh, United Kingdom of Great Britain and Northern Ireland
- 4School of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom of Great Britain and Northern Ireland
- 5Department of Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom of Great Britain and Northern Ireland
- 6Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands
- 7Lancaster Medical School, Lancaster University, Lancaster, United Kingdom of Great Britain and Northern Ireland
- 8Nuffield Department of Medicine, Pandemic Sciences Institute, University of Oxford, Oxford, United Kingdom of Great Britain and Northern Ireland
Abstract
Serological data provide important insights into SARS-CoV-2 transmission and immunity, particularly in regions with limited routine surveillance such as sub-Saharan Africa. However, antibody waning and boosting following reinfection or vaccination remain poorly characterised, complicating interpretation of serological measurements. Improved understanding of these dynamics is critical for accurate epidemiological inference. Modelling longitudinal serological data provides a means to quantify antibody kinetics and reconstruct infection histories. We analysed 15,679 neutralising antibody (nAb) titres from 1,675 unvaccinated, HIV-uninfected participants in urban (Lilongwe) and rural (Karonga) Malawi (February 2021–April 2022). NAb titres against ancestral B.1, Beta, Delta, and Omicron (BA.1/BA.2) viruses were measured using an HIV-based SARS-CoV-2 pseudotyped virus neutralisation assay. A multi-level Bayesian model was used to reconstruct infection histories and antibody kinetics. The model identified 429 infections (95% credible interval 417–441), including 39 (9.1%) that had not been identified by traditional seroconversion-based thresholds. Antibody levels waned rapidly, with 48% (0.403–0.560) of the acute boost remaining after three months and only 5% (0.027–0.098) after one year. Pre-Omicron infections generated stronger antibody boosts than Omicron infections. Responses varied, with individuals clustering into low and high responders. Cross-reactive responses extended across substantial antigenic distances - Omicron infections induced broader immunity. Seroincidence was higher in Lilongwe than in Karonga (0.41 vs. 0.27 infections per person per three months), driven by the early 2022 Omicron wave. Reinfections were common, particularly among adults and urban residents. SARS-CoV-2 nAb responses following infection were heterogeneous and declined rapidly. This rapid waning underscores the importance of vaccination for sustained protection, while cross-reactivity suggests only partial immunity from prior variants. Identifying reinfections is essential for understanding transmission and finding populations at higher repeat infection risk, particularly where routine surveillance is limited.
Related
- Distinct profiles and antibody production by splenic and lymph node antibody-secreting cells in Trypanosoma cruzi infection
- Contact in context: How land use histories, sociocultural practices, and animal profiles shape human-animal contact and zoonotic pathogen exposure in a fragmented forest of the Democratic Republic of Congo
- Immune genetic associations of antibody Fc-profiles across twins
- Enhanced Neutralizing Antibody Responses to Rhinovirus C and Age-Dependent Patterns of Infection
- Comparison of Giemsa and Hemacolor Staining Reveals Systematic Differences in Avian Leukocyte Profiles
BibTeX
@article{mccormack2026sarscov2,
title = {{SARS-CoV-2 neutralising antibody profiles reveal variant specific antibody dynamics and regional differences in infection histories in Malawi}},
author = {Mhairi J. McCormack and Louis Banda and Stephen Kasenda and Ellen C. Hughes and Amelia Crampin and Abena S. Amoah and Jonathan M. Read and Antonia Ho and Brian J. Willett and James A. Hay},
journal = {PLOS Global Public Health},
year = {2026},
month = oct,
doi = {10.1371/journal.pgph.0007133},
url = {https://journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.0007133},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - SARS-CoV-2 neutralising antibody profiles reveal variant specific antibody dynamics and regional differences in infection histories in Malawi
AU - Mhairi J. McCormack
AU - Louis Banda
AU - Stephen Kasenda
AU - Ellen C. Hughes
AU - Amelia Crampin
AU - Abena S. Amoah
AU - Jonathan M. Read
AU - Antonia Ho
AU - Brian J. Willett
AU - James A. Hay
PY - 2026
DA - 2026/10/01
JO - PLOS Global Public Health
DO - 10.1371/journal.pgph.0007133
UR - https://journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.0007133
AB - Serological data provide important insights into SARS-CoV-2 transmission and immunity, particularly in regions with limited routine surveillance such as sub-Saharan Africa. However, antibody waning and boosting following reinfection or vaccination remain poorly characterised, complicating interpretation of serological measurements. Improved understanding of these dynamics is critical for accurate epidemiological inference. Modelling longitudinal serological data provides a means to quantify antibody kinetics and reconstruct infection histories. We analysed 15,679 neutralising antibody (nAb) titres from 1,675 unvaccinated, HIV-uninfected participants in urban (Lilongwe) and rural (Karonga) Malawi (February 2021–April 2022). NAb titres against ancestral B.1, Beta, Delta, and Omicron (BA.1/BA.2) viruses were measured using an HIV-based SARS-CoV-2 pseudotyped virus neutralisation assay. A multi-level Bayesian model was used to reconstruct infection histories and antibody kinetics. The model identified 429 infections (95% credible interval 417–441), including 39 (9.1%) that had not been identified by traditional seroconversion-based thresholds. Antibody levels waned rapidly, with 48% (0.403–0.560) of the acute boost remaining after three months and only 5% (0.027–0.098) after one year. Pre-Omicron infections generated stronger antibody boosts than Omicron infections. Responses varied, with individuals clustering into low and high responders. Cross-reactive responses extended across substantial antigenic distances - Omicron infections induced broader immunity. Seroincidence was higher in Lilongwe than in Karonga (0.41 vs. 0.27 infections per person per three months), driven by the early 2022 Omicron wave. Reinfections were common, particularly among adults and urban residents. SARS-CoV-2 nAb responses following infection were heterogeneous and declined rapidly. This rapid waning underscores the importance of vaccination for sustained protection, while cross-reactivity suggests only partial immunity from prior variants. Identifying reinfections is essential for understanding transmission and finding populations at higher repeat infection risk, particularly where routine surveillance is limited.
SN - 2767-3375
ER -